Progress of Apatinib in Treatment of Non-small Cell Lung Cancer

Abstract

Non-small cell lung cancer (NSCLC) is the malignant tumor with the highest mortality in China.In recent years, considerable progress has been made in the treatment of NSCLC.The advent of numerous new drugs has significantly improved the survival of patients with advanced NSCLC.Apatinib mesylate is a novel oral small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor that has been approved for the third-line treatment of gastric cancer.At present, increased evidence confirmed that apatinib monotherapy has well efficacy on advanced NSCLC.Preclinical studies suggest that apatinib could reverse chemotherapy and EGFR TKI resistance.Therefore, apatinib combined with chemotherapy or EGFR TKI for advanced NSCLC has also been extensively explored.This article will give an overview of the basic and clinical progress of apatinib on NSCLC.

Keywords

• nsclc
• target therapy
• apatinib
• anti-angiogenesis